30.76USD-0.42%Mkt Cap: 3.58B USDP/E: —Last update: 2026-05-26
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue an…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap3.58B USD
Enterprise Value2.96B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-359.64M USD
Revenue/Share—
Last Price30.76 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees59
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS92686J1060
Valuation
P/E (Trailing)—
P/E (Forward)-6.76
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.51
EPS (TTM)-4.15
EPS (Forward)-4.54
52W Range
22.9639% of range43.15
52W High43.15 USD
52W Low22.96 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-56.28%
ROA-50.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-278.69M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-4.95%
Net Debt-602.96M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio5.72
Quick Ratio5.67
Book Value/Sh5.567 USD
Cash/Share5.193 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Strong Buy)
Target (Mean)92.33 USD
Target Range34.00 USD – 125.00 USD
# Analysts18
Ownership
Shares Out.116.11M
Float113.28M
Insiders2.78%
Institutions64.56%
Short Interest
Short Ratio9.4d
Short % Float20.62%
Short % Out.19.51%
Shares Short22.65M
Short (prev mo.)24.01M
Technical
SMA 5032.88 (-6.4%)
SMA 20032.61 (-5.7%)
Beta0.71
S&P 52W Chg28.31%
Avg Vol (30d)2.20M
Avg Vol (10d)1.90M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—